NCT00459654 - A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2007

Conditions

Prostate CancerNeoplasm Metastasis

Interventions

DRUG

Radium-223 dichloride (BAY88-8223)

Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.

DRUG

Saline

Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.

Trial Locations (3)

Linköping

Sundsvall

Nottingham